AVTX | tickerfilter.com

Fundamental analysis

31%

Profitability 35%

Dept financing 24%

Liquidity 27%

Performance 30%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0 0%

1 Month

-4.82%

3 Months

-3.30%

6 Months

-31.14%

1 Year

-27.16%

2 Year

-99.25%

Key data

Stock price

$8.20

P/E Ratio

-0.06

DAY RANGE

$8.20 - $8.80

EPS

-$0.47

52 WEEK RANGE

$4.25 - $22.47

52 WEEK CHANGE

-$0.11

MARKET CAP

7.239 M

YIELD

N/A

SHARES OUTSTANDING

1.034 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/07/2024

BETA

1.74

PUBLIC FLOAT

AVERAGE 10 VOLUME

$236,315

AVERAGE 30 VOLUME

$144,833

Company detail

CEO: Garry A. Neil
Region: US
Website: avalotx.com
Employees: 40
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Avalo Therapeutics, Inc. discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease and systemic juvenile idiopathic arthritis.

AVTX - Avalo Therapeutics, Inc.